DKK 377.00
+5.20 (+1.40%)
DKK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GUBRA.CO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2DNCT07702890Number of Treatment Emergent Adverse EventsRandomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Drug: GUB-UCN2, Placebo | Obesity, Type 2 Diabetes | 188 | Dec 2028 | ≤ 865 d | 2026-07-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19